In most cancer types, PTEN loss was associated with a higher abundance of CD4+ lymphocytes, M1 macrophages, and FoxP3+ T regulatory cells, along with increased expression of immune checkpoints such as LAG3 and IDO1, indicating an immunosuppressive tumor microenvironment [44]. This evidence concerns the gene PTEN and cancer.